RG
SBBP

Redmile Group’s Strongbridge Biopharma plc. SBBP Stock Holding History

Redmile Group’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,500
Closed -$56K – 87
2018
Q4 		$56K Buy
+12,500
New +$61K ﹤0.01% 77

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Redmile Group's SBBP Position: Q1 2019 in Review

Redmile Group sold out of Strongbridge Biopharma plc. (SBBP) in Q1 2019, closing a stake of 12,500 shares — an estimated $56K sold.

Redmile Group first reported a position in SBBP in Q4 2018 and held it in 1 quarter. The position peaked at $56K in Q4 2018. 51 funds tracked by Wall St. Rank hold SBBP as of Q1 2019.

  • Redmile Group reported no remaining Strongbridge Biopharma plc. position as of Q1 2019 after selling out during the quarter.
  • Redmile Group sold 12,500 Strongbridge Biopharma plc. shares in Q1 2019, an estimated $56K.
  • Redmile Group first reported a position in Strongbridge Biopharma plc. in Q4 2018 and held it in 1 quarter.
  • Redmile Group's Strongbridge Biopharma plc. position peaked at $56K in Q4 2018.
  • 51 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q1 2019.

Based on Redmile Group's 13F filing for Q1 2019, filed 15 May 2019.